Bernhard Kirschbaum

Chairman

Bernhard Kirschbaum studied biochemistry and physiological chemistry at the University of Konstanz and received his PhD in 1989. He moved on to work at the Rockefeller University and the Pasteur Institute before making a career in the pharmaceutical industry where he covered a broad range of technological and disease areas. In his most recent position, Dr. Kirschbaum served as head of Global Research and Early Development at Merck Serono where he was a member of the board.

Christian Schetter

Christian Schetter has over 20 years’ industry experience in life sciences, and is Managing Director of venture capital firm Arix Bioscience. As CEO he built immuno-oncology company Rigontec and lead it to an acquisition by MSD for a total consideration of EUR 464 m. Previously he was President and CEO of Fresenius Biotech and led the successful spin-out from the Neopharm Group to form Neovii Biotech. As SVP of European Operations, he was part of the leadership team which built Coley Pharmaceuticals from inception, a NASDAQ IPO and the acquisition by Pfizer in 2007. Christian has a PhD in Molecular Biology and hold research positions at the Max Planck Institute and the Scripps Research Institute.

Holger Reithinger

Holger Reithinger is General Partner and heads the Munich Office of venture capital firm Forbion. He is also member of the investment committee of the Hightech-Gründer Fonds, Germany’s biggest early-stage and seed investor. Prior to joining Forbion, he was Partner at Global Life Science Ventures and Director at Germany’s healthcare practice of 3i and Investment Manager at Technologieholding VC. Dr. Reithinger studied Molecular Biology/Microbial Biology and Biochemistry at the Universities of Heidelberg and Munich. He holds a PhD in Biochemistry from the Max-Planck-Institute of Biophysics, which he obtained under the supervision of Prof. Dr. Arne Skerra in the department of Prof. Dr. Hartmut Michel.

Christian Schneider

Christian Schneider, Managing Partner of Vesalius Biocapital, has been a venture capital executive for 20 years. He gained extensive experience in the areas of diagnostics, medtech, and therapeutics in the corporate life science and venture capital industry. Previously he held positions of increasing responsibility at Boehringer Mannheim, Centocor, and Johnson&Johnson. As a managing partner of VC firm PolyTechnos, he was responsible for OncoMethylome (IPO, 2006), Devgen (IPO, 2005) and Jerini (IPO, 2005). He was support partner for Addex (IPO, 2007) and BiPar (USD 500m sale to Sanofi-Aventis, 2009). He joined Vesalius in 2008 and is responsible for the portfolio companies Skyline (write-off), Activaero (EUR 130m sale to Vectura, 2014), Ventaleon, OMEICOS, Humedics and Mecuris where he serves on the boards. Dr. Schneider holds a doctorate degree in veterinary medicine (1992) and a PhD in immunology (1995), both from the University of Munich, Germany, and an MBA with focus on healthcare administration from Penn State University, Pennsylvania (1999).

Ute Mercker

Ute Mercker, a seasoned Venture Capital executive with more than 20 years’ experience, serves as Prokuristin / Investment Director at IBB Beteiligungsgesellschaft. Since 1997 she is overseeing the Life Science portfolio of the regional venture capital funds of Berlin. She managed investments into companies such as Jerini (IPO 2005, USD 521 acquired by Shire in 2008), Scienion (Secondary 2016), Scopis (2017 sale to Stryker), EternyGen and Selfapy, in most cases serving on the supervisory boards of these companies, too. Ute Mercker holds an MBA from the Freie Universität Berlin.

Peter Seiler

Head of Treasury Vice President SMS GmbH




Taro Inaba

Taro Inaba is Founder and Managing Partner at Remiges Ventures. He has over 29 years of business experience including 19 years in start-up financing and company creation. At Remiges, Taro is engaged in technology sourcing, company creation, leading negotiation for investments and serving as director for seven of the Remiges’ portfolio companies. Prior to establishing Remiges Ventures, he spent 13 years at divisions of Mitsui & Co., Ltd. engaged in venture investment activities where he built and managed the biopharma investment team and investment portfolio. He served as President & CEO of Mitsui & Co. Venture Partners in Menlo Park, California from 2008 to 2009. Taro holds a B.E. in Polymer Chemistry, Kyoto University and MBA from European University. Taro is a CFA charter holder.

Wolf-Hagen Schunck

Wolf-Hagen Schunck is biochemist at the Max Delbrück Center for Molecular Medicine in Berlin-Buch. He has over 30 years of research experience in the field of cytochrome P450 (CYP)-derived bioactive lipid mediators. Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) laying the scientific basis for the foundation of OMEICOS. In collaboration with fellow co-founder Dr. John R. Falck, he developed robust synthetic analogues for in vivo administration. The current work of Dr. Schunck is focused on further elucidating the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.